Soluble receptors for vascular endothelial growth factor (sVEGFR1/sVEGFR2) in infantile hemangioma

Growth Factors

Volumn 28, Issue 6, 2010, Pages 417-425

  Przewratil, Przemyslaw ^a   Sitkiewicz, Anna ^a   Andrzejewska, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Hemangioma; Soluble VEGF receptors; VEGF

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CAPILLARY HEMANGIOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMANGIOMA; HUMANS; INFANT; MALE; NEOVASCULARIZATION, PATHOLOGIC; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78650563908     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2010.505566     Document Type: Article

References (25)

1. Ach T, Thiemeyer D, Hoeh AE, Schaal KB, Dithmar S. 2010. Intravitreal bevacizumab for retinal capillary haemangioma: Longterm results. Acta Ophthalmol 88:e137-e138.
2. Anthony FW, Evans PW, Wheeler T, Wood PJ. 1997. Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann Clin Biochem 34: 276-280. (Pubitemid 27236931)
3. Barnés CM, Christison-Lagay EA, Folkman J. 2007. The placenta theory and the origin of infantile hemangioma. Lymphat Res Biol 5:245-255.
4. Carmeliet P. 2005. Angiogenesis in life, disease and medicine. Nature 438:932-936. (Pubitemid 43093958)
5. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS. 2004. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2:315-326. (Pubitemid 39025294)
6. Folkman J. 2007. Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 42:1-11. (Pubitemid 46043358)
7. Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, Chamlin SL, Baselga E, Garzon MC, Nopper AJ, Siegel DH, Mathes EW, Goddard DS, Bischoff J, North PE, Esterly NB. 2005. Infantile hemangiomas: Current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas. April 7-9,2005, Bethesda, Maryland. Pediatr Dermatol 22:383-406. (Pubitemid 43960991)
8. Frischer JS, Huang J, Serur A, Kadenhe A, Yamashiro DJ, Kandel JJ. 2004. Biomolecular markers and involution of hemangiomas. J Pediatr Surg 39:400-404. (Pubitemid 38338357)
9. Fuh G, Li B, Crowley C, Cunningham B, Wells JA. 1998. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 273: 197-204. (Pubitemid 28204970)
10. Ilhan N, Ilhan N, Deveci F. 2004. Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem 37: 840-845. (Pubitemid 39141129)
11. Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR. 2008. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14: 1236-1246.
12. Kendall RL,Wang G, Thomas KA. 1996. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324-328. (Pubitemid 26331903)
13. Korzeniewska M, Kolomecki K, Stepień H, Naze M, Stepień T, Kuzdak K. 2005. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors]. Endokrynol Pol 56:39-44, Polish.
14. Li Zhang, Lin X, Wang W, Zhuang X, Dong J, Qi Z, Hu Q. 2005. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation. Plast Reconstr Surg 116:200-204. (Pubitemid 40944039)
15. Marler JJ, Fishman SJ, Kilroy SM. 2005. Increased expression of urinary matrix metalloproteinases parallels extent and activity of vascular anomalies. Pediatrics 116:38-45.
16. Przewratil P, Sitkiewicz A, Andrzejewska E. 2010. Local serum levels of vascular endothelial growth factor in infantile hemangioma: Intriguing mechanism of endothelial growth. Cytokine 49:141-147.
17. Roberts JM, Rajakumar A. 2009. Preeclampsia and soluble fms-like tyrosine kinase 1. J Clin Endocrinol Metab 94: 2252-2254.
18. Shibuya M. 2006. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469-478. (Pubitemid 44714526)
19. Shibuya M. 2006. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1):Adual regulator for angiogenesis.Angiogenesis 9:225-230.
20. Soker S, Svahn CM, Neufeld G. 1993. Vascular endothelial growth factor is inactivated by binding to a2-macroglobulin and the binding is inhibited by heparin. J Biol Chem 268: 7685-7691. (Pubitemid 23120336)
21. Swidzińska E, Ossolińska M, Naumnik W, Izycki T, Kucejko W, Chyczewska E. 2004. [Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer]. Pneumonol Alergol Pol 72:389-394, Polish. (Pubitemid 40532982)
22. Takahashi H, Shibuya M. 2005. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109:227-241. (Pubitemid 41337127)
23. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. 1994. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:88-95. (Pubitemid 24332901)
24. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
25. Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J. 2004. Endothelial progenitor cells in infantile hemangioma. Blood 103: 1373-1375. (Pubitemid 38168651)